The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen.

The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers could be inflating drug costs in the U.S., in the latest and likely ...

The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an interim staff report on pharmacy benefit managers (PBM). Sens.

The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ influence over specialty generic ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly ... the end of the Biden administration, the FTC report is the strongest statement yet that holds ...

The nation's three largest pharmacy ... drug," an FTC spokesperson told reporters in a press briefing, adding that the figure was "probably an underestimate." Pharmacy benefit managers, or PBMs ...

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...